363185-87-9

Basic information

• Product Name: Benzoic acid, 2-amino-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-, methyl ester
• Synonyms: Benzoic acid, 2-amino-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-, methyl ester;methyl 2-amino-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoate;2-AMino-5-(4,4,5,5-tetraMethyl-1,3,2-dioxaborolan-2-yl)benzoic acid Methyl ester;Methyl 2-aMino-5-(tetraMethyl-1,3,2-dioxaborolan-2-yl)benzoate;4-AMino-3-Methoxycarbonylphenylboronic Acid Pinacol Ester;Methyl 2-amino-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)
• CAS NO: 363185-87-9
• Molecular Formula: C₁₄H₂₀BNO₄
• Molecular Weight: 277.13
• Mol File: 363185-87-9.mol
• Article Data: 9

Chemical Properties

• Boiling Point: 404°C at 760 mmHg
• Flash Point: 198.2°C
• Appearance: /
• Density: 1.13g/cm³
• Vapor Pressure: 9.73E-07mmHg at 25°C
• Refractive Index: 1.52
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• CAS DataBase Reference: Benzoic acid, 2-amino-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-, methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Benzoic acid, 2-amino-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-, methyl ester(363185-87-9)
• EPA Substance Registry System: Benzoic acid, 2-amino-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-, methyl ester(363185-87-9)

Safety Data

• Hazardous Substances Data: 363185-87-9(Hazardous Substances Data)

Usage

General Description

Benzoic acid, 2-amino-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-, methyl ester is a chemical compound with the molecular formula C12H17BO4N. It is a methyl ester derivative of benzoic acid that contains an amino group and a boron-containing ring. Benzoic acid, 2-amino-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-, methyl ester is often used in organic synthesis and medicinal chemistry as a building block or intermediate for the synthesis of various pharmaceuticals and agrochemicals. It is also used as a reagent in the preparation of complex organic molecules and as a component in the production of fine chemicals. Due to its structural properties, it has the potential to exhibit various biological and pharmacological activities, making it an important molecule in drug discovery and development.

InChI:InChI=1/C14H20BNO4/c1-13(2)14(3,4)20-15(19-13)9-6-7-11(16)10(8-9)12(17)18-5/h6-8H,16H2,1-5H3

Upstream product

• 77317-55-6 methyl 2-amino-5-iodobenzoate 
• 25015-63-8 4,4,5,5-tetramethyl-[1,3,2]-dioxaboralane 
• 73183-34-3 bis(pinacol)diborane 
• 52727-57-8 5-bromo-2-aminobenzoic acid methyl ester 

Downstream Products

• 1319197-39-1 (4'-amino-3'-(hydroxymethyl)-6-methylbiphenyl-2-yl)(pyrrolidin-1-yl)methanone 
• 1319197-40-4 4-amino-2'-methyl-6'-(pyrrolidine-1-carbonyl)biphenyl-3-carbaldehyde 
• 1319194-80-3 (2-(2-amino-3-((1S,4S)-2-oxa-5-azabicyclo[2.2.1]heptan-5-yl)quinolin-6-yl)-3-methylphenyl)(pyrrolidin-1-yl)methanone 
• 1319194-82-5 (2-(2-amino-3-cyclopentenylquinolin-6-yl)-3-methylphenyl)(pyrrolidin-1-yl)methanone 

Relevant articles and documents

ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASES ASSOCIATED WITH P13K MODULATION

The disclosure relates to compounds of Formula (I) as allosteric chromenone inhibitors of phosphoinositide 3-kinase (PI3K) useful in the treatment of diseases or disorders associated with PI3K modulation, Formula (I), or a prodrug, solvate, enantiomer, st

PFKFB3 INHIBITORS AND THEIR USES

This disclosure relates to new phthalimide and isoindolinone derivatives and other PFKFB3 inhibitors for use in the treatment of diseases. The invention further relates to pharmaceutical compositions containing such PFKFB3 inhibitors, methods of preparation thereof, methods for their use as therapeutic agents, and methods of preparation of a medicament for use in therapy, as well as kits and other inventiions comprising such PFKFB3 inhibitors. These PFKFB3 inhibitors are useful for the treatment and prophylaxis of cancer, neurodegenerative diseases, autoimmune diseases, inflammatory disorders, multiple sclerosis, metabolic diseases, inhibition of angiogenesis and other diseases and conditions, where the modulation of PFKFB3 and/or PFKFB4 has beneficial effect as well as neuroprotection.

THIENOPYRANONES AND FURANOPYRANONES AS KINASE, BROMODOMAIN, AND CHECKPOINT INHIBITORS

The invention relates to compounds and methods of treating diseases including but not limited to, cancer, non-cancer proliferative disease, sepsis, autoimmune disease, viral infaction, atheroscleosis. Type 1 or 2 diabetes, obesity, inflammatory disease, o